Prioritizing Health Care: Reform Gains Early Momentum
This article was originally published in RPM Report
Health care reform advocates think the stars are aligned for a major push toward universal coverage under President-elect Barack Obama. They aren’t about to let the free-falling economy get in the way.
You may also be interested in...
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.
The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?